| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/03/2023 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 08/21/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...|
Docs:
|
"2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURED CONVERTIBLE PROMISSORY NOTE",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURITIES PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT",
"SKYE BIOSCIENCE, INC. SECURED NOTE AND WARRANT PURCHASE AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody" |
|
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu... |
| 01/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/03/2022 |
8-K
| Quarterly results |
| 09/01/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/31/2022 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 07/20/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 01/31/2022 |
5
| Emerald Health Sciences Inc. (10% Owner) has filed a Form 5 on Skye Bioscience, Inc. |
| 01/31/2022 |
SC 13D/A
| Emerald Health Sciences Inc. reports a 23.4% stake in Skye Bioscience, Inc. |
| 01/05/2022 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 0.4% stake in Skye Bioscience, Inc. |
| 12/20/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/10/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/10/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/15/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/28/2021 |
8-K
| Quarterly results |
| 09/28/2021 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/14/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 05/07/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|